CDSCO Clinical Trial Approval: India’s Regulatory Pathway Explained

India runs clinical trial approval through a single national regulator rather than the dual-track (regulator plus separate national ethics body) model used in some other jurisdictions. The Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulatory authority under the Ministry of Health and Family Welfare, is the Central Licensing Authority (CLA) for new drugs and clinical trials, and the Drugs Controller General of India (DCGI) heads CDSCO and exercises the CLA’s approval powers. A trial cannot enrol its first participant until both the DCGI’s clinical trial permission and a registered Ethics Committee’s approval are in place. This guide walks through CDSCO’s role, the approval process under the New Drugs and Clinical Trials (NDCT) Rules, 2019, realistic timelines, and a January 2026 amendment that sponsors sometimes over-read as speeding up trial approval itself — it does not.

Who Regulates Clinical Trials in India

Three elements matter for a new drug or investigational new drug (IND) trial in India:

• CDSCO is India’s national regulator for drugs, medical devices, and clinical trials, functioning under the Ministry of Health and Family Welfare’s Directorate General of Health Services. It is headquartered in New Delhi with a network of zonal, sub-zonal, and port offices.
• The DCGI (Drugs Controller General of India) heads CDSCO and, as the Central Licensing Authority under the NDCT Rules, 2019, is the officer who grants (or refuses) permission to conduct a clinical trial for a new drug or IND.
• Ethics Committees registered with the Central Licensing Authority provide the independent ethical review a trial also needs. Registration is mandatory for any Ethics Committee reviewing clinical trials, bioavailability/bioequivalence (BA/BE) studies, or biomedical health research, and a registration is valid for five years.

Applications, registrations, and status tracking run through SUGAM, CDSCO’s online portal for new drug, clinical trial, and licensing submissions — broadly the Indian counterpart to systems like the EU’s CTIS or the US FDA’s electronic submission gateways referenced in CASRAI’s EMA vs. FDA comparison.

The Governing Regulation: New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials (NDCT) Rules, 2019, issued under India’s Drugs and Cosmetics Act, 1940, is the current framework governing clinical trials, new drug approval, Ethics Committee registration, and BA/BE studies in India. It replaced the clinical-trial provisions previously scattered across Schedule Y of the older Drugs and Cosmetics Rules, consolidating them into one dedicated rulebook with defined timelines, defined roles for Ethics Committees and Subject Expert Committees (SECs, which provide technical review input to the DCGI on specific applications such as new chemical entities), and a structured set of CT-series application forms.

Step by Step: From Protocol to First Patient In

1. Register (or confirm) the Ethics Committee. The site’s Ethics Committee must be registered with the Central Licensing Authority using Form CT-01 before it can issue a valid clinical trial opinion; an existing registration is valid for five years, so an already-registered site may skip straight to protocol review.
2. Submit the clinical trial permission application. The sponsor (or its authorised Indian representative) files Form CT-04 with CDSCO through SUGAM, along with the protocol, investigator’s brochure, informed consent documents, and the supporting data set out in the NDCT Rules’ Second Schedule.
3. DCGI and Subject Expert Committee review. CDSCO’s technical review may route the application to a relevant SEC for expert input, particularly for new chemical entities or higher-risk categories; queries raised during review generally pause the review clock until the sponsor responds.
4. Parallel Ethics Committee review. The trial’s protocol and consent materials go to the registered Ethics Committee at the site in parallel with the CDSCO submission, similar in spirit to how other jurisdictions structure regulatory and ethics review — see CASRAI’s guide to ANVISA’s dual-track process in Brazil for a comparison point.
5. Grant of permission. Once CDSCO’s review is satisfied, the DCGI issues permission to conduct the trial on Form CT-06. Enrolment cannot begin until this permission and the Ethics Committee’s approval are both in hand.
6. Register the trial. Indian trials must be registered with the Clinical Trials Registry – India (CTRI), hosted by the Indian Council of Medical Research’s National Institute of Medical Statistics and a Primary Registry in the WHO International Clinical Trials Registry Platform (ICTRP) network — the same principle covered in CASRAI’s guide to clinical trial registration and reporting compliance.

Timelines: What to Expect

Under the NDCT Rules, 2019, CDSCO is required to decide a clinical trial permission application within 90 working days of receipt. If the application is rejected, the sponsor may request the DCGI to reconsider within 60 working days of the rejection, on payment of the prescribed fee. As with any published regulatory deadline, this is a ceiling rather than a typical outcome — a complete, well-prepared dossier that avoids repeated query cycles is generally reviewed faster than the statutory maximum, while an incomplete submission can consume most or all of the 90 working days in query-and-response cycles alone.

The January 2026 Amendment: Faster Test Licences, Not a Faster Trial Approval

In January 2026, India’s Ministry of Health and Family Welfare notified the New Drugs and Clinical Trials (Amendment) Rules, 2026 (G.S.R. 46(E), dated 20 January 2026). Sponsors researching this amendment should be precise about what it actually changes, because it is easy to conflate with the main clinical-trial permission timeline above:

• Test licence timelines were cut from 90 to 45 working days. The amendment reduces the statutory processing timeline for test licences under NDCT Rules provisions covering manufacture of new drugs/INDs for the purposes of clinical trials, BA/BE studies, and examination/testing (Form CT-10 territory) from 90 working days to 45 working days.
• A prior-intimation mechanism replaces licensing for certain non-commercial manufacture. For specified categories — including manufacture for clinical trials and for BA/BE studies — the sponsor can proceed on filing an intimation to CDSCO and receiving acknowledgement, rather than waiting for a substantive licence approval. Government reporting on the amendment describes this as capable of saving a minimum of roughly 90 days across the drug development lifecycle.
• Prior-permission requirements for certain low-risk BA/BE studies were removed under the same amendment.

What did not change: the headline 90-working-day statutory timeline for CDSCO’s decision on a clinical trial permission application (Form CT-04) under the base NDCT Rules, 2019, is a separate track from the test-licence and manufacturing-intimation provisions the 2026 amendment revised. Sponsors and research administrators should treat the 2026 amendment as a real, meaningful reduction in the manufacturing/test-licence critical path feeding into a trial — not as a change to the clinical trial permission timeline itself. Given how recently this amendment was notified, confirm current requirements and any implementing guidance directly at cdsco.gov.in before finalising a country-level project timeline.

Common Pitfalls for International Sponsors

• Treating CDSCO permission and Ethics Committee approval as sequential when they can run in parallel. Submitting the Ethics Committee review only after CDSCO clears the application (or vice versa) adds one track’s full review period onto the other’s, unnecessarily.
• Assuming an unregistered site’s Ethics Committee can review a protocol. Form CT-01 registration is a prerequisite, not a formality that runs alongside the trial application — an unregistered committee’s opinion is not valid grounds to proceed.
• Confusing the 2026 test-licence timeline reduction with the clinical trial permission timeline. As above, these are different tracks under different rule provisions with different statutory clocks.
• Underestimating Subject Expert Committee routing for novel therapeutic categories. Applications that route to an SEC add a review layer beyond a standard administrative check, and scheduling around SEC meeting cadence is a common source of delay outside CDSCO’s control.
• Missing CTRI registration as a distinct action. Registration in CTRI is not automatic on receipt of CT-06 permission and has its own timing expectations, comparable to the prospective-registration norms described in CASRAI’s entry on prospective clinical trial registration.

How India Compares to Other Jurisdictions

India’s model — a single national regulator (CDSCO/DCGI) plus a registered, site-level Ethics Committee, both required before enrolment — sits structurally between a single-authority system and the more formally bifurcated national regulator/national ethics commission split used in Brazil under ANVISA and CEP/CONEP. It differs in mechanics from China’s NMPA clinical trial approval process and from the framework compared in CASRAI’s EMA vs. FDA guide, though the underlying principle — that a trial needs both a regulatory authorisation and an independent ethics opinion before it can start — is consistent with the ICH Good Clinical Practice framework nearly all of these jurisdictions reference. For sponsors running a multi-country programme, the practical lesson is the same one that applies across every jurisdiction CASRAI covers in this series: build each country’s regulatory and ethics timeline into the master trial plan individually, rather than assuming one jurisdiction’s approval cadence transfers to another.

Frequently Asked Questions

What is the difference between CDSCO and the DCGI?

CDSCO is the regulatory organisation; the DCGI is the individual officer who heads CDSCO and, as the Central Licensing Authority under the NDCT Rules, 2019, exercises the statutory power to grant or refuse clinical trial permissions and new drug approvals.

How long does CDSCO take to approve a clinical trial?

The NDCT Rules, 2019 set a 90-working-day statutory deadline for CDSCO’s decision on a clinical trial permission application, with a further 60-working-day window to request reconsideration if the application is rejected. This is a maximum, not a guaranteed or typical turnaround.

Did the January 2026 amendment shorten clinical trial approval to 45 days?

No. The New Drugs and Clinical Trials (Amendment) Rules, 2026 reduced the statutory timeline for test licences (covering manufacture of investigational product for trials and BA/BE studies) from 90 to 45 working days and introduced a prior-intimation route for certain non-commercial manufacture. The main clinical trial permission timeline under the base NDCT Rules, 2019 is unchanged.

What form registers an Ethics Committee in India?

Form CT-01 is the application for registration (or renewal) of an Ethics Committee reviewing clinical trials, BA/BE studies, or biomedical health research, submitted to the Central Licensing Authority; registration is valid for five years.

Where must an Indian clinical trial be registered?

In the Clinical Trials Registry – India (CTRI), maintained by the Indian Council of Medical Research’s National Institute of Medical Statistics and a WHO ICTRP Primary Registry.

Does CDSCO regulate medical devices the same way as drugs?

Medical devices in India are regulated under the Medical Device Rules, 2017, a separate regulatory track from the NDCT Rules, 2019 covered in this guide, though CDSCO is the regulator for both.